

## **Membership of Pancreatic cancer guideline Committee**

The Committee will operate as an advisory Committee to NICE's Board, developing a guideline on the diagnosis and management of pancreatic cancer in adults]

The terms of reference and standing orders for the Committee can be found in [appendix D of Developing NICE guidelines: the manual](#).

The Committee has 16 members.

## Membership list

Agreed Constituency	Name	Job Title, Organisation	Comment
<b>Chair</b>			
	John Primrose	Professor of Surgery, University of Southampton	
<b>Clinical Lead</b>			
	John Neoptolemos	The Owen and Ellen Evans Chair of Surgery, University of Liverpool and The Royal Liverpool & Broadgreen University Hospital NHS Trust	John left the committee, August 2017.
<b>Core members</b>			
Diagnostic radiologist  Interventional radiologist	Mark Callaway	Consultant Radiologist, Bristol Royal Infirmary, University Hospitals, Bristol NHS Foundation Trust	
Cellular pathologist with expertise in pancreatic cancer	Fiona Campbell	Consultant Gastrointestinal Pathologist, Royal Liverpool University Hospital	
Palliative care specialist	Margred Capel	Consultant in Palliative Medicine, George Thomas Hospice	
Pancreatic surgeon	Richard Charnley	Consultant Hepatobiliary and Pancreatic Surgeon, Freeman Hospital, Newcastle upon Tyne	

Committee membership list – Pancreatic Cancer Guideline Committee

Medical oncologist	Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust and University of Cambridge	
Clinical nurse specialist	Dawn Elliot	UGI Clinical Nurse Specialist, Northumbria Healthcare Foundation Trust	
Lay member	Lesley Goodburn	Lay member	
Lay member	Anna Jewell	Lay member	
Lay member	Suzanne Joharchi	Lay member	
Dietitian	Laura McGeeney	Specialist Pancreatic Dietitian, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust	
Clinical oncologist	Somnath Mukherjee	Senior Clinical Researcher & Consultant Clinical Oncologist, CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford & Churchill Hospital	
Endoscopist (EUS and ERCP)	Kofi Oppong	Consultant Gastroenterologist, Newcastle upon Tyne University Hospitals NHS Trust	
Pancreatic	Derek O'Reilly	Consultant	

Committee membership list – Pancreatic Cancer Guideline Committee

surgeon		Hepatobiliary and Pancreatic Surgeon, Manchester Royal Infirmary, Central Manchester NHS Foundation Trust	
Clinical nurse specialist	Philip Whelan	Macmillan Clinical Nurse Specialist, Royal Liverpool University Hospital	

**Date last reviewed:** 25/01/2018

## Declaration of Interests

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Professor John Primrose	Professor of Surgery, University of Southampton	Chief investigator and involved in designing the trial protocol for FACS (randomised controlled trial to assess the cost-effectiveness of intensive versus no scheduled follow-up in patients who have undergone resection for colorectal cancer with curative intent). Funded by NIHR HTA [declared on application 23.7.15]	Non-personal financial non-specific	Declare and participate
Professor John Primrose	Professor of Surgery, University of Southampton	Chief investigator and involved in designing the trial protocol for ORANGE-2 (Open Versus Laparoscopic Hemihepatectomy). Funded by Maastricht University Medical Center [declared on application 23.7.15]	Non-personal financial non-specific	Declare and participate
Professor John Primrose	Professor of Surgery, University of Southampton	Chief investigator and involved in designing the trial protocol for BILCAP (A randomised clinical trial evaluating adjuvant chemotherapy with capecitabine compared to expectant treatment alone following surgery for biliary tract cancer). Funded by CRUK [declared on application 23.7.15]	Non-personal financial non-specific	Declare and participate
Professor John Primrose	Professor of Surgery, University of Southampton	Chief investigator and involved in designing the trial protocol for EPOC B (An exploratory study to investigate the optimal scheduling of chemotherapy in patients with operable colorectal liver metastases). Funded by CTAAC [declared on application 23.7.15]	Non-personal financial non-specific	Declare and participate
Professor John Primrose	Professor of Surgery, University of Southampton	Chief investigator and involved in designing the trial protocol for New EPOC (A prospective randomised open label trial of oxaliplatin / irinotecan plus fluorouracil versus oxaliplatin / irinotecan plus fluorouracil and cetuximab pre and post operatively in patients with resectable colorectal liver	Non-personal financial non-specific	Declare and participate

Committee membership list – Pancreatic Cancer Guideline Committee

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
		metastases requiring chemotherapy). Funded by CRUK [declared on application 23.7.15]		
Professor John Primrose	Professor of Surgery, University of Southampton	Chief investigator and involved in designing the trial protocol for ACTICCA-1 (Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma. A randomized, multidisciplinary, multinational AIO/DGAV/DGVS phase III trial). Funded by CTAAC. [declared on application 23.7.15]	Non-personal financial non-specific	Declare and participate
Professor John Primrose	Professor of Surgery, University of Southampton	Chief investigator and involved in designing the trial protocol for Trans EPOC (tissue collection for the EPOC study). Funded by CTAAC. [declared on application 23.7.15]	Non-personal financial non-specific	Declare and participate
Professor John Primrose	Professor of Surgery, University of Southampton	Chief investigator and involved in designing the trial protocol for Trans BILCAP (tissue collection for the BILCAP study). Funded by CRUK [declared on application 23.7.15]	Non-personal financial non-specific	Declare and participate
Professor John Primrose	Professor of Surgery, University of Southampton	Co-investigator (not involved in designing the trial protocol) for the TACE-2 trial (a randomised placebo-controlled, double blinded, phase III trial evaluating sorafenib in combination with transarterial chemoembolisation (TACE) in patients with unresectable hepatocellular carcinoma (HCC)). Funded by Bayer Ltd. [declared on application 23.7.15]	Non-personal financial non-specific	Declare and participate
Professor John Primrose	Professor of Surgery, University of Southampton	Department receives an infrastructure grant from CRUK which employs a clinical lecturer in general surgery. [declared on application 23.7.15]	Non-personal financial non-specific	Declare and participate

Committee membership list – Pancreatic Cancer Guideline Committee

<b>Name</b>	<b>Job title, organisation</b>	<b>Declarations of Interest, date declared</b>	<b>Type of interest</b>	<b>Decision taken</b>
Professor John Neoptolemos	The Owen and Ellen Evans Chair of Surgery, University of Liverpool and The Royal Liverpool & Broadgreen University Hospital NHS Trust	Received payment in September 2015 from Merck Serono Global for attending an advisory board for Pancreatic Cancer [declared on application 20.7.15]	Personal financial	Withdraw from discussion of any topics which include interventions made by Merck Serono Global until September 2016
Professor John Neoptolemos	The Owen and Ellen Evans Chair of Surgery, University of Liverpool and The Royal Liverpool & Broadgreen University Hospital NHS Trust	Received payment in September 2014 from Amgen for giving a lecture on the role of adjuvant therapies for pancreatic cancer at a GI forum in Oslo, Norway [declared on application 20.7.15]	Personal financial specific	Declare and participate as interest lapsed in September 2015 (before guideline development started)
Professor John Neoptolemos	The Owen and Ellen Evans Chair of Surgery, University of Liverpool and The Royal Liverpool & Broadgreen University Hospital NHS Trust	Received payment in March 2014 from Abbott for giving a lecture on surgery criteria for resectability and results in pancreatic cancer at the Gastroenterology and jscopy service, Santa Maria Hospital, Lisbon. [declared on application 20.7.15]	Personal financial specific	Declare and participate as interest lapsed in March 2015
Professor John Neoptolemos	The Owen and Ellen Evans Chair of Surgery, University of Liverpool and The Royal Liverpool & Broadgreen University Hospital NHS Trust	Received payment from KAEL-GemVax between September 2013 and August 2014 for the development of GV1001 (prognostic/predictive marker of survival in pancreatic cancer). [declared on application 20.7.15]	Personal financial specific	Declare and participate as interest lapsed in August 2015 (before guideline development started)
Professor John Neoptolemos	The Owen and Ellen Evans Chair of Surgery, University of Liverpool and The Royal Liverpool & Broadgreen University Hospital NHS Trust	Received an educational travel grant from NUCANA to attend the ASCO meeting in Chicago in 2015. [declared on application 20.7.15]	Personal financial non-specific	Declare and participate
Professor John	The Owen and Ellen Evans Chair	NIHR Senior Investigator from April 2011 to 2016 [declared on	Personal financial	Declare and

Committee membership list – Pancreatic Cancer Guideline Committee

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Neoptolemos	of Surgery, University of Liverpool and The Royal Liverpool & Broadgreen University Hospital NHS Trust	application 20.7.15]	non-specific	participate
Professor John Neoptolemos	The Owen and Ellen Evans Chair of Surgery, University of Liverpool and The Royal Liverpool & Broadgreen University Hospital NHS Trust	Has financial responsibility for an account which is used for pancreatic cancer research. No contributions to the fund from industry. [declared on application 20.7.15]	Non-personal financial non-specific	Declare and participate
Professor John Neoptolemos	The Owen and Ellen Evans Chair of Surgery, University of Liverpool and The Royal Liverpool & Broadgreen University Hospital NHS Trust	<p>Director of the Cancer Research UK Liverpool Cancer Trials Unit, which encompasses the CRUK trials unit (funded by CRUK), North West Surgical Trials Centre (funded by CRUK and Royal College of Surgeons of England) and the NIHR Clinical Trial Unit (Funded by NIHR). Within this unit:</p> <p>CRUK – funds a Senior Research Nurse.</p> <p>There is a laboratory services agreement with Merck. This agreement has been discharged and the surplus money is being used to support research within the department.</p> <p>Expects to sign a research agreement shortly to provide Taiho with immunohistochemistry staining of samples for the JASPAC-01 trial (Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer).</p> <p>Several trials being undertaken by the trials unit are supported by industry and this support includes funding/part funding of posts within the trials unit. [declared on application 20.7.15]</p>	Non-personal financial specific	Declare and participate as decisions on how funding is allocated and spent are made collectively.



Committee membership list – Pancreatic Cancer Guideline Committee

<b>Name</b>	<b>Job title, organisation</b>	<b>Declarations of Interest, date declared</b>	<b>Type of interest</b>	<b>Decision taken</b>
Professor John Neoptolemos	The Owen and Ellen Evans Chair of Surgery, University of Liverpool and The Royal Liverpool & Broadgreen University Hospital NHS Trust	Member of the independent trial steering committee (advise on safety, no involvement in designing trial protocol) for a randomized controlled trial of Hemopatch to prevent post-operative pancreatic duct fistula on the pancreatic stump after distal pancreatectomy. Funded by Baxter. [declared on application 20.7.15]	Non-personal financial non-specific	Declare and participate
Professor John Neoptolemos	The Owen and Ellen Evans Chair of Surgery, University of Liverpool and The Royal Liverpool & Broadgreen University Hospital NHS Trust	Co-principle investigator (designed trial protocol) for a prospective, phase II, double-blinded, multicentre, randomised clinical trial comparing combination gemcitabine and vandetanib therapy with gemcitabine therapy alone in advanced pancreatic cancer. Funded by Astra Zeneca. Trial has now closed but data analysis and reporting of results is ongoing. [declared on application 20.7.15]	Non-personal financial specific	Withdraw from discussion of any topics which include vandetanib as an intervention
Professor John Neoptolemos	The Owen and Ellen Evans Chair of Surgery, University of Liverpool and The Royal Liverpool & Broadgreen University Hospital NHS Trust	National co-investigator (designed trial protocol) on ACELARATE trial (Phase III, open label, multicentre randomized clinical trial comparing Acelarin with Gemcitabine in patients with metastatic pancreatic adenocarcinoma). Funded by NUCANA. [declared on application 20.7.15]	Non-personal financial specific	Withdraw from discussion of any topics which include acelararin as an intervention
Professor John Neoptolemos	The Owen and Ellen Evans Chair of Surgery, University of Liverpool and The Royal Liverpool & Broadgreen University Hospital NHS Trust	Co-investigator (provides scientific input and interpretation of data) for study on the role of monocytes in the metastatic process: identification of novel molecular targets to fight pancreatic cancer. Funded by Pancreatic Cancer Research Fund. [declared on application 20.7.15]	Non-personal financial non-specific	Declare and participate
Professor	The Owen and	Principle investigator	Non-	Withdrawn

Committee membership list – Pancreatic Cancer Guideline Committee

<b>Name</b>	<b>Job title, organisation</b>	<b>Declarations of Interest, date declared</b>	<b>Type of interest</b>	<b>Decision taken</b>
John Neoptolemos	Ellen Evans Chair of Surgery, University of Liverpool and The Royal Liverpool & Broadgreen University Hospital NHS Trust	(responsible for doing the research and deciding how funds should be spent) on a study on the role of Eotaxin-1/CCR3 in human pancreatic cancer and as a prognostic and/or predictive marker of survival by GV1001. Funded by KAEL-GemVax. [declared on application 20.7.15]	personal financial specific	from discussion of any topics which include Eotaxin-1/CCR3 or GV1001 as interventions
Professor John Neoptolemos	The Owen and Ellen Evans Chair of Surgery, University of Liverpool and The Royal Liverpool & Broadgreen University Hospital NHS Trust	Co-investigator (provides scientific input and interpretation of data) for a study on validation of serum biomarkers for pancreatic cancer detection. Funded by North West Cancer Research. [declared on application 20.7.15]	Non-personal financial specific	Declare and participate as not involved in designing trial protocol and trial not funded by industry
Professor John Neoptolemos	The Owen and Ellen Evans Chair of Surgery, University of Liverpool and The Royal Liverpool & Broadgreen University Hospital NHS Trust	Co-principal investigator (collect tissues and data) for European Study Group for Pancreatic Cancer Trial 5F prospective sample collection - ESPAC-5FT. Funded by Cancer Research UK [declared on application 20.7.15]	Non-personal financial specific	Declare and participate as not involved in designing trial protocol and trial not funded by industry
Professor John Neoptolemos	The Owen and Ellen Evans Chair of Surgery, University of Liverpool and The Royal Liverpool & Broadgreen University Hospital NHS Trust	Co-principal investigator for ESPAC-5F Four arm, prospective, multicentre, randomised Phase II trial of immediate surgery compared with neoadjuvant chemotherapies and neoadjuvant chemoradiotherapy. Funded by Cancer Research UK [declared on application 20.7.15]	Non-personal financial specific	Declare and participate as not involved in designing trial protocol and trial not funded by industry
Professor John Neoptolemos	The Owen and Ellen Evans Chair of Surgery, University of Liverpool and The Royal Liverpool & Broadgreen University Hospital NHS Trust	Co-principal investigator for European Study Group for Pancreatic Cancer (ESPAC)- Trial 4. Combination versus single agent adjuvant chemotherapy in resectable pancreatic cancer. Funded by Cancer Research UK [declared on application 20.7.15]	Non-personal financial specific	Declare and participate as not involved in designing trial protocol and trial not funded by industry

Committee membership list – Pancreatic Cancer Guideline Committee

<b>Name</b>	<b>Job title, organisation</b>	<b>Declarations of Interest, date declared</b>	<b>Type of interest</b>	<b>Decision taken</b>
Professor John Neoptolemos	The Owen and Ellen Evans Chair of Surgery, University of Liverpool and The Royal Liverpool & Broadgreen University Hospital NHS Trust	Co-principal investigator (collect tissues and data) ESPAC 4T: European Study Group for Pancreatic Cancer Trial 4 prospective sample collection. Funded by Cancer Research UK [declared on application 20.7.15]	Non-personal financial specific	Declare and participate as not involved in designing trial protocol and trial not funded by industry
Professor John Neoptolemos	The Owen and Ellen Evans Chair of Surgery, University of Liverpool and The Royal Liverpool & Broadgreen University Hospital NHS Trust	Co-principal investigator for PANasta trial (Cattell Warren versus Blumgart techniques of pancreatico-jejunostomy following pancreatoduodenectomy - a double blinded multi-centred trial). Funded by Cancer Research UK. [declared on application 20.7.15]	Non-personal financial specific	Declare and participate as not involved in designing trial protocol and trial not funded by industry
Professor John Neoptolemos	The Owen and Ellen Evans Chair of Surgery, University of Liverpool and The Royal Liverpool & Broadgreen University Hospital NHS Trust	Co-principal investigator for study on stratification of adjuvant chemotherapeutic response to allow personalised choice of pyrimidine prodrug: based on levels of transporters and enzymes involved in initial metabolism. Funded by Cancer Research UK [declared on application 20.7.15]	Non-personal financial non-specific	Declare and participate
Professor John Neoptolemos	The Owen and Ellen Evans Chair of Surgery, University of Liverpool and The Royal Liverpool & Broadgreen University Hospital NHS Trust	Principle investigator (designed trial protocol) for study on antioxidants and magnesium for the treatment of pain in hereditary and idiopathic chronic pancreatitis. Funded by Pharma Nord. [declared on application 20.7.15]	Non-personal financial non-specific	Declare and participate
Professor John Neoptolemos	The Owen and Ellen Evans Chair of Surgery, University of Liverpool and The Royal Liverpool & Broadgreen University Hospital NHS Trust	Signed a non-disclosure agreement with Biopharma Ltd to provide advice on an interventional non-medical treatment for pancreatic cancer. Will be paid a fee for advice [5 <sup>th</sup> GC meeting on 15.9.16]	Personal financial specific	Declare and must withdraw from any discussion which include an intervention made by Redhill Biopharma

Committee membership list – Pancreatic Cancer Guideline Committee

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
				Ltd
Professor John Neoptolemos	The Owen and Ellen Evans Chair of Surgery, University of Liverpool and The Royal Liverpool & Broadgreen University Hospital NHS Trust	Provided consultancy on 28/10/2016 to Sun Biopharma on SBP-101 (a polyamine inhibitor for pancreatic cancer). Will be paid a fee for advice [GCM7 DOI form from 09.12.2016]	Personal financial specific	Declare and withdraw from any topics that include SBP-101 as an intervention (no topics are looking at this intervention)
Professor John Neoptolemos	The Owen and Ellen Evans Chair of Surgery, University of Liverpool and The Royal Liverpool & Broadgreen University Hospital NHS Trust	Provided consultancy to Erytech, a French biopharmaceutical company. [6 <sup>th</sup> GC meeting on 25/10/2016]	Personal financial nonspecific	Declare and must withdraw from any discussion which include an intervention made by Erytech
Professor John Neoptolemos	The Owen and Ellen Evans Chair of Surgery, University of Liverpool and The Royal Liverpool & Broadgreen University Hospital NHS Trust	Joint PI on a trial investigating the prospective validation of IMMray™ PanCan-d (a new diagnostic method in pancreatic cancer) in Europe. Sponsored by Immunovia [declared on DOI 09.12.2016 GCM7]	Non-personal financial, non-specific	Declare and participate
Professor John Neoptolemos	The Owen and Ellen Evans Chair of Surgery, University of Liverpool and The Royal Liverpool & Broadgreen University Hospital NHS Trust	Provided consultancy for RedxOncology on the development of porcupine inhibitor, RXC004, in patients with pancreatic cancer harbouring RNF43 LoF mutations. No fee paid at this time. [DOI 09.12.2016 GCM7]	Personal non-financial, non-specific	Declare and participate
John Neoptolemos	The Owen and Ellen Evans Chair of Surgery, University of Liverpool and The Royal Liverpool & Broadgreen University Hospital NHS Trust	Joint PI on a trial investigating the prospective validation of IMMray™ PanCan-d (a new diagnostic method in pancreatic cancer) in Europe. Sponsored by Immunovia [DOI 13.12.2016]	Non-personal financial, non-specific	Declare and participate as this
John Neoptolemos	The Owen and Ellen Evans Chair	Provided consultancy for RedxOncology on the	Personal non-	Declare and participate

Committee membership list – Pancreatic Cancer Guideline Committee

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
	of Surgery, University of Liverpool and The Royal Liverpool & Broadgreen University Hospital NHS Trust	development of porcupine inhibitor, RXC004, in patients with pancreatic cancer harbouring RNF43 LoF mutations. No fee paid at this time. [DOI 13.12.2016]	financial, non-specific	
John Neoptolemos	The Owen and Ellen Evans Chair of Surgery, University of Liverpool and The Royal Liverpool & Broadgreen University Hospital NHS Trust	On the advisory board for TARGOVAX. A Norway company looking to use KRAS vaccine as part of adjuvant treatment in pancreatic cancer. 23rd March 2017.  Confidential results of a small randomised phase II trial.  A further meeting is now planned for the 22nd May 2017. [11/05/2017]	Personal financial, non-specific	Declare and participate
Mark Callaway	Consultant Radiologist, Bristol Royal Infirmary	Visiting Professor, University of the West of England, appointed in Dec 2015 [declared on application 13.01.16]	Personal financial non-specific	Declare and participate
Mark Callaway	Consultant Radiologist, Bristol Royal Infirmary	Partner in Bristol Radiology LLP [declared on application 13.01.16]	Personal financial specific	Declare and participate as long as topics only look at standard radiology interventions used in the NHS (approved by NICE)
Mark Callaway	Consultant Radiologist, Bristol Royal Infirmary	Director of MCallaway Medical Imaging Ltd [declared on application 13.01.16]	Personal financial specific	Declare and participate as long as topics only look at standard radiology interventions used in the NHS (approved by NICE)
Mark Callaway	Consultant Radiologist, Bristol Royal Infirmary	Trustee of Cobalt Health, appointed in Dec 2015 [declared on application	Non-financial personal	Declare and participate

Committee membership list – Pancreatic Cancer Guideline Committee

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
		13.01.16]	non-specific	
Mark Callaway	Consultant Radiologist, Bristol Royal Infirmary	Trustee of the Royal College of Radiologists [declared on application 13.01.16]	Non-financial personal non-specific	Declare and participate
Mark Callaway	Consultant Radiologist, Bristol Royal Infirmary	Received an honorarium from Succinct in March 2016 for co-chairing a round table discussion about the role of transarterial chemoembolization for hepatocellular carcinoma. This will be used to write an article for Bayer UK.	Personal financial non-specific	Declare and participate
Professor Fiona Campbell	Consultant Gastrointestinal Pathologist, Royal Liverpool University Hospital	On the medical advisory board for Pancreatic Cancer UK. Reviews content of patient information resources [declared on application 23.2.16]	Non-financial specific	Declare and participate
Professor Fiona Campbell	Consultant Gastrointestinal Pathologist, Royal Liverpool University Hospital	Collaborator providing pathology input to the ESPAC-4 (EUROPEAN STUDY GROUP FOR PANCREATIC CANCER - TRIAL 4. Combination versus single agent chemotherapy in resectable pancreatic ductal and peri-ampullary cancers). Funded by CRUK [declared on application 23.2.16]	Non-personal financial specific	Declare and participate as no supervisory responsibility for the trial
Professor Fiona Campbell	Consultant Gastrointestinal Pathologist, Royal Liverpool University Hospital	Collaborator providing pathology input to the VIP (A prospective, phase II, double blinded, multicentre, randomised clinical trial comparing combination gemcitabine and vandetanib therapy with gemcitabine therapy alone in locally advanced or metastatic pancreatic carcinoma.) Funded by Astra Zeneca [declared on application 23.2.16]	Non-personal financial specific	Declare and participate as no supervisory responsibility for the trial
Professor Fiona Campbell	Consultant Gastrointestinal Pathologist, Royal Liverpool University Hospital	Collaborator providing pathology input to the PET-PANC (The impact of combined modality positron emission tomography with computerised tomography scanning (PET/CT)	Non-personal financial specific	Declare and participate as no supervisory responsibility for the trial

Committee membership list – Pancreatic Cancer Guideline Committee

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
		in the diagnosis and management of pancreatic cancer.) Funded by NIHR Health Technology Assessment [declared on application 23.2.16]		
Professor Fiona Campbell	Consultant Gastrointestinal Pathologist, Royal Liverpool University Hospital	Collaborator providing pathology input to the ESPAC-5F (European Study Group for Pancreatic Cancer Trial 5F Four arm, prospective, multicentre, randomised feasibility trial of immediate surgery compared with neoadjuvant chemotherapies and neoadjuvant chemoradiotherapy.) Funded by CRUK [declared on application 23.2.16]	Non-personal financial specific	Declare and participate as no supervisory responsibility for the trial
Professor Fiona Campbell	Consultant Gastrointestinal Pathologist, Royal Liverpool University Hospital	Collaborator providing pathology input to the ENDCaP (Enhanced Neoplasia Detection and Cancer Prevention in Chronic Colitis: A Multicentre test accuracy study). Funded by NIHR Efficacy and Mechanism Evaluation [declared on application 23.2.16]	Non-personal financial non-specific	Declare and participate as no supervisory responsibility for the trial
Professor Fiona Campbell	Consultant Gastrointestinal Pathologist, Royal Liverpool University Hospital	Collaborator providing pathology input to the PANasta (Cattell Warren versus Blumgart techniques of pancreatico-jejunostomy following pancreato-duodenectomy - a double blinded multicentred trial). Funded by CRUK [declared on application 23.2.16]	Non-personal financial specific	Declare and participate as no supervisory responsibility for the trial
Professor Fiona Campbell	Consultant Gastrointestinal Pathologist, Royal Liverpool University Hospital	Collaborator providing pathology input to the ACELARATE (A Phase III, open label, multicentre randomised clinical study comparing Acelarin (NUC1031) with Gemcitabine in patient with metastatic pancreatic carcinoma.) funded by NuCana BioMed Ltd [declared on application 23.2.16]	Non-personal financial specific	Declare and participate as no supervisory responsibility for the trial
Professor Fiona	Consultant Gastrointestinal	Collaborator providing pathology input to the	Non-personal	Declare and participate

Committee membership list – Pancreatic Cancer Guideline Committee

<b>Name</b>	<b>Job title, organisation</b>	<b>Declarations of Interest, date declared</b>	<b>Type of interest</b>	<b>Decision taken</b>
Campbell	Pathologist, Royal Liverpool University Hospital	FOxTROT (Fluoropyrimidine, Oxaliplatin & Targeted Receptor pre-Operative Therapy for colon cancer. A randomised trial assessing whether preoperative chemotherapy and/or an anti-EGFR monoclonal antibody improves outcome in high-risk operable colon cancer.). Funded by CRUK [declared on application 23.2.16]	financial non-specific	
Professor Fiona Campbell	Consultant Gastrointestinal Pathologist, Royal Liverpool University Hospital	Committee member of the Pancreatic Society of GB and Ireland. [declared on application 23.2.16]	Non-financial specific	Declare and participate
Professor Fiona Campbell	Consultant Gastrointestinal Pathologist, Royal Liverpool University Hospital	Collaborator providing pathology input to European Study Group for Pancreatic Cancer Trial 4 prospective sample collection - ESPAC 4T. Funded by CRUK [1.4.16]	Non-personal financial specific	Declare and participate as no supervisory responsibility for the trial
Professor Fiona Campbell	Consultant Gastrointestinal Pathologist, Royal Liverpool University Hospital	Collaborator providing pathology input to Whole Genome Sequencing of Pancreatic Cancers from Patients Selected from the ESPAC Trials to Identify Novel Pathways and Networks Determining Response to Chemotherapy and Chemoradiotherapy. Funded by CRUK [1.4.16]	Non-personal financial non-specific	Declare and participate
Professor Fiona Campbell	Consultant Gastrointestinal Pathologist, Royal Liverpool University Hospital	Collaborator providing pathology input to European Study Group for Pancreatic Cancer Trial 5F prospective sample collection – ESPAC-5FT. Funded by CRUK [1.4.16]	Non-personal financial specific	Declare and participate as no supervisory responsibility for the trial
Professor Fiona Campbell	Consultant Gastrointestinal Pathologist, Royal Liverpool University Hospital	Collaborator providing pathology input to Impact of tumour-associated myeloid cells on cancer stemness and chemotherapy-resistance. Funded by North West Cancer Research Fund [1.4.16]	Non-personal financial non-specific	Declare and participate
Professor Fiona Campbell	Consultant Gastrointestinal Pathologist, Royal Liverpool	Collaborator providing pathology input to Validation of serum biomarkers for pancreatic cancer detection. Funded by North West Cancer	Non-personal financial specific	Declare and participate as no supervisory responsibility



Committee membership list – Pancreatic Cancer Guideline Committee

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
	University Hospital	Research [1.4.16]		for the trial
Professor Fiona Campbell	Consultant Gastrointestinal Pathologist, Royal Liverpool University Hospital	Collaborator providing pathology input to MicroRNA profiling in pancreatic stellate cells: validation and assessment of potential to predict response to treatment. Funded by Pancreatic Cancer UK [1.4.16]	Non-personal financial non-specific	Declare and participate
Professor Fiona Campbell	Consultant Gastrointestinal Pathologist, Royal Liverpool University Hospital	Collaborator providing pathology input to Stratification of adjuvant chemotherapeutic response to allow personalised choice of pyrimidine prodrug: based on levels of transporters and enzymes involved in initial metabolism. Funded by CRUK [1.4.16]	Non-personal financial non-specific	Declare and participate
Professor Fiona Campbell	Consultant Gastrointestinal Pathologist, Royal Liverpool University Hospital	Collects pancreatic cancer tissue samples for a PhD student, who is funded jointly by RedX Oncology & the Pancreas Biomedical Research Unit, University of Liverpool [1.4.16]	Non-personal financial non-specific	Declare and participate
Professor Fiona Campbell	Consultant Gastrointestinal Pathologist, Royal Liverpool University Hospital	Providing pathology input into the JASPAC-01 trial, (Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer).  Have just started selecting areas of tumour to be analysed by immunohistochemistry. [20/03/2017]	Personal non-financial, specific.	Declare and participate as no supervisory responsibility for the trial
Professor Fiona Campbell	Consultant Gastrointestinal Pathologist, Royal Liverpool University Hospital	Co-author on the submitted HTA report for the PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality <sup>18</sup> fluorine-2-fluoro-2-deoxy-D-glucose positron emission tomography with computed tomography scanning in the diagnosis and management of pancreatic cancer trial. [16/10/2017]	Non-Personal non-financial, specific.	Declare and participate in the meeting, but Chair asked Dr. Campbell to not participate in the discussion of the PET-PANC study.
Professor Fiona	Consultant Gastrointestinal	Very occasionally (one or two cases a month) report the	Personal financial,	Declare and participate.

Committee membership list – Pancreatic Cancer Guideline Committee

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Campbell	Pathologist, Royal Liverpool University Hospital	<p>histology on gastrointestinal/ hepatopancreatobiliary specimens taken in the private sector.</p> <p>The payment for reporting specimens from private patients stopped in November 2015.</p> <p>[22/11/2017]</p>	non-specific.	There are no questions in the guideline about reporting pathology specimens.
Dr Margred Capel	Consultant in Palliative Medicine, George Thomas Hospice	Local principal investigator on the OPTCARE NEURO trial (Evaluation of the clinical and cost-effectiveness of Short-term Integrated Palliative Care Services (SIPC) to OPTimise CARE for people with advanced long-term Neurological conditions. Funded by NIHR Health Services and Delivery Research. Responsible for administering the trial protocol locally. No involvement in designing the trial protocol. [declared on application 4.2.16]	Non-personal financial non-specific	Declare and participate
Dr Margred Capel	Consultant in Palliative Medicine, George Thomas Hospice	Member of the Association of Palliative Medicine professional standards committee – for example write symptom control guidelines. [declared on application 4.2.16]	Non-financial non-specific	Declare and participate
Mr Richard Charnley	Consultant Hepatobiliary and Pancreatic Surgeon, Freeman Hospital, Newcastle upon Tyne	Submitted patients to the ESPAC trials (all funded by CRUK). Involved in the study design for ESPAC-5 [declared on application 6.1.16]	Non-financial non-specific	Declare and participate
Mr Richard Charnley	Consultant Hepatobiliary and Pancreatic Surgeon, Freeman Hospital, Newcastle upon Tyne	Responsible for a general pancreatic research fund (used to support research and students) and a fund used specifically for research into ascinar cell tumours. No industry contributions to either fund. [declared on application 6.1.16]	Non-personal financial non-specific	Declare and participate
Mr Richard Charnley	Consultant Hepatobiliary and Pancreatic	On the Medical Advisory Board for Pancreatic Cancer UK. Assists with general awareness	Non-financial non-	Declare and participate

Committee membership list – Pancreatic Cancer Guideline Committee

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
	Surgeon, Freeman Hospital, Newcastle upon Tyne	raising and member of the panel who score grant applications. [declared on application 6.1.16]	specific	
Mr Richard Charnley	Consultant Hepatobiliary and Pancreatic Surgeon, Freeman Hospital, Newcastle upon Tyne	Published a pamphlet on pancreatic cancer supplementation in 2010 which was sponsored by Abbott. Received a fee [declared on application 6.1.16]	Personal financial specific	Declare and participate as interest has lapsed
Mr. Richard Charnley	Consultant Hepatobiliary and Pancreatic Surgeon, Freeman Hospital, Newcastle upon Tyne	Co-author on the submitted HTA report for the 'PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality <sup>18</sup> fluorine-2-fluoro-2-deoxy-D-glucose positron emission tomography with computed tomography scanning in the diagnosis and management of pancreatic cancer trial'. Recruited several patients into the PET_PANC study. [22/11/2017]	Non-Personal non-financial, specific.	Declare and participate in the meeting, but Chair asked Mr. Charnley to not participate in the discussion of the PET-PANC study.
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Received an honorarium for attendance at an advisory board from Celgene on abraxane in pancreatic cancer in March 2015. [declared on application 7.12.15]	Personal financial specific	Withdraw from discussion of any topics which include abraxane as an intervention until March 2016
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Received an honorarium for attendance at an advisory board from Roche on Melanoma systemic therapies in June 2015 [declared on application 7.12.15]	Personal financial non-specific	Declare and participate
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University	Received an honorarium for attendance at an advisory board from Novartis on Melanoma systemic therapies in June 2015 [declared on application 7.12.15]	Personal financial non-specific	Declare and participate

Committee membership list – Pancreatic Cancer Guideline Committee

<b>Name</b>	<b>Job title, organisation</b>	<b>Declarations of Interest, date declared</b>	<b>Type of interest</b>	<b>Decision taken</b>
	Hospitals NHS Foundation Trust			
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Received an honorarium for attendance at an advisory board from BMS on Melanoma systemic therapies in July 2015 [declared on application 7.12.15]	Personal financial non-specific	Declare and participate
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Received an honorarium for attendance at an advisory board from Baxalta on liposomal irinotecan for advanced pancreatic cancer in November 2015 [declared on application 7.12.15]	Personal financial specific	Withdraw from discussion of any topics which include liposomal irinotecan as an intervention until March 2016
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Received an honorarium for attendance at an advisory board from Roche on Melanoma systemic therapies in December 2015 [declared on application 7.12.15]	Personal financial non-specific	Declare and participate
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Received an honorarium for attendance at an advisory board from Roche on Melanoma systemic therapies in January 2016 [declared on application 7.12.15]	Personal financial non-specific	Declare and participate
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Received payment from Roche for a presentation on Overview of melanoma therapies to Roche employees as part of melanoma awareness week in May 2015 [declared on application 7.12.15]	Personal financial non-specific	Declare and participate
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology,	Received payment from Novartis for a presentation on Use of systemic therapies for melanoma as demonstrated by	Personal financial non-specific	Declare and participate

Committee membership list – Pancreatic Cancer Guideline Committee

<b>Name</b>	<b>Job title, organisation</b>	<b>Declarations of Interest, date declared</b>	<b>Type of interest</b>	<b>Decision taken</b>
	Cambridge University Hospitals NHS Foundation Trust	patient cases in June 2015 [declared on application 7.12.15]		
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Received payment from Celgene for a presentation on treatment of advanced pancreatic cancer in September 2015 [declared on application 7.12.15]	Personal financial specific	Withdraw from discussion of topics including interventions made by Celgene until September 2016
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Received reimbursement of travel, registration and accommodation expenses for 30 May-2 June 2015 ASCO conference, Chicago from BMS [declared on application 7.12.15]	Personal financial non-specific	Declare and participate
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Received reimbursement of travel, registration and accommodation expenses for September 2015, ECCO conference from BMS [declared on application 7.12.15]	Personal financial non-specific	Declare and participate
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Received reimbursement of travel, registration and accommodation expenses for November 2015, Society of Melanoma Research from BMS [declared on application 7.12.15]	Personal financial non-specific	Declare and participate
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Chairs an ISDMC on behalf of Celgene for the Celgene-sponsored international multiple myeloma trial, MM007 trial (previously received a fee and reimbursement of travel expenses) [declared on application 7.12.15]	Personal financial non-specific	Declare and participate
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical	Previously received a fee and reimbursement of travel expenses for being a member	Personal financial non-	Declare and participate

Committee membership list – Pancreatic Cancer Guideline Committee

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
	Oncology, Cambridge University Hospitals NHS Foundation Trust	of the MM026 multiple myeloma trial [declared on application 7.12.15]	specific	
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Chief investigator for AVAST-M trial (randomised trial evaluating the VEGF inhibitor, bevacizumab (Avastin), as adjuvant therapy following resection of AJCC stage IIB (T4aN0M0), IIC (T4bN0M0) and III (TxN1-2M0) cutaneous melanoma). Designed the trial protocol. Funded by CRUK. [declared on application 7.12.15]	Non-personal financial non-specific	Declare and participate
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Chief investigator for SIEGE trial (Randomised phase II trial to investigate two different schedules of nab-paclitaxel (Abraxane) combined with gemcitabine as first line treatment for metastatic pancreatic ductal adenocarcinoma). Designed the trial protocol. Funded by Celgene. [declared on application 7.12.15]	Non-personal financial specific	Withdraw from discussion of topics that include abraxane as an intervention
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Co-applicant for SCALOP2 – (A multi-centre randomised study of induction chemotherapy followed by capecitabine (+/- nelfinavir) with high or standard dose radiotherapy for locally advanced non-metastatic pancreatic cancer). Involved in designing trial protocol. Funded by CRUK and Celgene. [declared on application 7.12.15]	Non-personal financial specific	Withdraw from discussion of topics that include nelfinavir as an intervention
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Principle investigator for ESPAC-4 (Combination versus single agent chemotherapy in resectable pancreatic ductal and peri-ampullary cancers). Responsible for delivering the trial protocol locally. Funded by CRUK. [declared on application 7.12.15]	Non-personal financial specific	Declare and participate as no supervisory responsibility for the trial

Committee membership list – Pancreatic Cancer Guideline Committee

<b>Name</b>	<b>Job title, organisation</b>	<b>Declarations of Interest, date declared</b>	<b>Type of interest</b>	<b>Decision taken</b>
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Principle investigator for AFACT (Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer). Responsible for delivering the trial protocol locally. Funded by Celgene. [declared on application 7.12.15]	Non-personal financial specific	Declare and participate as no supervisory responsibility for the trial
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Principle investigator for PACMEL (A randomised phase 2 study of paclitaxel with or without GSK1120212 or pazopanib in advanced wt BRAF melanoma). Responsible for delivering the trial protocol locally. Funded by GSK. [declared on application 7.12.15]	Non-personal financial non-specific	Declare and participate
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Principle investigator for IMCgp100/01 (Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma). Responsible for delivering the trial protocol locally. Funded by Immunocore Ltd. [declared on application 7.12.15]	Non-personal financial non-specific	Declare and participate
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Principle investigator for EORTC 18081 (Adjuvant peginterferon alfa-2b for 2 years vs Observation in patients with an ulcerated primary cutaneous melanoma with T(2-4) bN0M0: a randomized phase III trial of the EORTC Melanoma Group). Responsible for delivering the trial protocol locally. Funded by EORTC. [declared on application 7.12.15]	Non-personal financial non-specific	Declare and participate
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University	Principle investigator for COLUMBUS (Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma).	Non-personal financial non-specific	Declare and participate

Committee membership list – Pancreatic Cancer Guideline Committee

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
	Hospitals NHS Foundation Trust	Responsible for delivering the trial protocol locally. Funded by Novartis. [declared on application 7.12.15]		
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Principle investigator for Millenium (Study of MLN2480 in Patients With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Patients With Metastatic Melanoma). Responsible for delivering the trial protocol locally. Funded by Millenium Pharmaceuticals Inc. [declared on application 7.12.15]	Non-personal financial non-specific	Declare and participate
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Principle investigator for EORTC 1325 (Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma). Responsible for delivering the trial protocol locally. Funded by Merck [declared on application 7.12.15]	Non-personal financial non-specific	Declare and participate
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Principle investigator for Sel-PAC (A Randomised three arm Randomised three arm, open label, Phase II study of continuous Selumetinib versus continuous or interrupted Selumetinib in combination with weekly Paclitaxel in metastatic Uveal Melanoma). Responsible for delivering the trial protocol locally. Funded by Astra Zeneca [declared on application 7.12.15]	Non-personal financial non-specific	Declare and participate
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Principle investigator for ACELARATE (Phase III, open label, multicentre randomised clinical study comparing Acelarin (NUC1031) with Gemcitabine in patient with metastatic pancreatic carcinoma.) Responsible for delivering the trial protocol locally. Funded by NuCana BioMed Ltd [declared on application 7.12.15]	Non-personal financial specific	Declare and participate as no supervisory responsibility for the trial
Dr Pippa	Consultant and	Principle investigator for	Non-	Declare and



Committee membership list – Pancreatic Cancer Guideline Committee

<b>Name</b>	<b>Job title, organisation</b>	<b>Declarations of Interest, date declared</b>	<b>Type of interest</b>	<b>Decision taken</b>
Corrie	Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	ACTICCA1 (A randomized, multidisciplinary, multinational AIO/DGAV/DGVS phase III trial of adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma). Responsible for delivering the trial protocol locally. Funded by CTAAC [declared on application 7.12.15]	personal financial non-specific	participate
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Will be principal investigator on the forthcoming PERM trials (melanoma) [declared on application 7.12.15]	Non-personal financial non-specific	Declare and participate
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Has financial sign off (up to £5K) on a fund for melanoma and a fund for pancreatic cancer. Funds are used for research. No contributions to either fund from industry. [declared on application 7.12.15]	Non-personal financial non-specific	Declare and participate
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Scientific advisor to Pancreatic Cancer UK. No fees received. Provides advice on strategy and reviews/updates patient information [declared on application 7.12.15]	Non-financial personal specific	Declare and participate
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Trustee for Melanoma Focus. No fees received. Oversees strategy and general function of the charity. [declared on application 7.12.15]	Non-financial personal non-specific	Declare and participate
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology,	Provided an overview of systemic therapy for advanced pancreatic cancer to Celgene in 2013. This was recorded and	Non-financial personal	Declare and participate as interest

Committee membership list – Pancreatic Cancer Guideline Committee

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
	Cambridge University Hospitals NHS Foundation Trust	put on their website and also used in promotional literature. [declared on application 7.12.15]	specific	has lapsed
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Second author on a pamphlet on Pancreatic cancer – nabpaclitaxel. Gives an overview of the disease and the use of the drug in clinical practice – based on a review of existing literature. No fee received. Put together by Celgene and made available to clinicians. [declared on application 7.12.15]	Non-financial personal specific	Declare and participate
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Attended ESMO Oncology Conference Denmark 2016. Celgene paid for accommodation and flights. General oncology conference. [GCM7 13/12/2016]	Personal financial, non-specific	Declare and participate (expenses are within the NICE Hospitality policy)
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Attended ESMO Oncology Conference Denmark 2016. Celgene paid for accommodation, flights and registration. General oncology conference. [GCM 13/12/2017]	Personal financial, non-specific	Declare and participate (expenses are within the NICE Hospitality policy)
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Undertook discussion with Nordic Pharma between 2014 - 2015 regarding request to supply S-1 as an IMP for an academic trial comparing S-1 with gemcitabine in poor performance metastatic pancreatic cancer patients. The trial proposal was submitted to CRUK FSC for research funding support but was not supported. Nordic Pharma was not able to provide research funding for the trial so the concept was not taken forward. Discussions ended September 2015. [20/03/2017]	Personal non-financial, specific	Declare and participate
Dr Pippa	Consultant and	UK Chief Investigator for HALO	Non-	Declare and

Committee membership list – Pancreatic Cancer Guideline Committee

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Corrie	Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	301 trial - international phase III trial sponsored by Halozyme inc currently recruiting: A Phase 3, Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus nab-Paclitaxel and Gemcitabine in Subjects with Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma. [20/03/2017]	personal financial, non-specific.	participate.
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	UK Chief Investigator for Artist 1 - international phase III trial sponsored by ARMO Inc due to open in July 2017: A Randomised Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing Regimen. [20/03/2017]	Non-personal financial, specific.	Declare and participate.
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Co-investigator for a new pancreatic cancer trial due to open this year which is funded by Plexxicon and the CRUK New Agents Committee:  A Phase Ib/IIa Trial Combining the Selective Dual Trk/Fms Kinase Inhibitor PLX-7486 with gemcitabine as first or second-line treatment, in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) and cancer-related pain This is an early phase academic study sponsored by the NHS Greater Glasgow & Clyde / University of Glasgow	Non-personal financial, specific.	Declare and participate.

Committee membership list – Pancreatic Cancer Guideline Committee

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
		currently under development. My role is in protocol development, study conduct and patient recruitment. The study is likely to open to recruitment towards the end of 2017. [20/03/2017]		
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Co-investigator on new multicentre locally advanced pancreatic cancer trial, PanCO, which my institution will participate in:  An open label, single arm pilot study of OncoSil™, administered to study participants with unresectable locally advanced pancreatic adenocarcinoma, given in combination with FOLFIRINOX or gemcitabine+nab-paclitaxel chemotherapies  Sponsor: OncoSil Medical Ltd [20/03/2017]	Non-personal financial, specific.	Declare and participate.
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Principal Investigator: PRECISION Panc network of clinical trials. £10 million investment from Cancer Research UK. Funding from Celgene and Astra Zeneca	Non-personal financial, specific	Declare and participate
Dr Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Private practice undertaken, treating patients with pancreaticobiliary cancers and melanoma.  For pancreatic cancer patients provided the same treatments as available on the NHS.  [22/11/2017]	Personal, financial, specific	No action taken as they were no further committee meetings after this point.
Dawn Elliot	UGI Clinical Nurse Specialist, Northumbria Healthcare Foundation Trust	External Examiner for Hull University – BA and MSC in Gastroenterology. Paid a fee of £300/year. Performs quality assurance of marks given by course tutors. [declared on	Personal financial non-specific	Declare and participate

Committee membership list – Pancreatic Cancer Guideline Committee

<b>Name</b>	<b>Job title, organisation</b>	<b>Declarations of Interest, date declared</b>	<b>Type of interest</b>	<b>Decision taken</b>
		application 24.2.16]		
Dawn Elliot	UGI Clinical Nurse Specialist, Northumbria Healthcare Foundation Trust	Is a signatory on a small fund (max £700) used for buying items for patients and supporting nurse training. Fund is from patient donations only – no industry contribution [declared on application 24.2.16]	Non-personal financial non-specific	Declare and participate
Lesley Goodburn	Lay member	Employed as a Service Partner for Insight and Involvement at NHS Midlands and Lancashire Commissioning Support Unit. Involves advising on patient experience and getting patients involved in health and decision making. No specific focus on pancreatic cancer. [declared on application 25.2.16]	Personal financial non-specific	Declare and participate
Lesley Goodburn	Lay member	Participated in a patient/carer board for Pancreatic Cancer UK in December 2015. Received reimbursement of travel expenses [declared on application 25.2.16]	Non-financial personal specific	Declare and participate
Lesley Goodburn	Lay member	Given £150 by Pancreatic Cancer UK to run a support group for patients with pancreatic cancer. Decides what the money is used on – typically mobile phones, business cards, printing. [declared on application 25.2.16]	Non-personal financial specific	Declare and participate
Lesley Goodburn	Lay member	Started a new position as NHS England as a Patient Experience manager until June 2017. [GCM7 13.12.2016]	Personal non-financial, non-specific	Declare and participate.
Lesley Goodburn	Lay member	Started a new position as NHS England as a Patient Experience manager [GCM 13/12/2017]	Personal financial, non-specific	Declare and participate.
Lesley Goodburn	Lay member	Attended a PCUK study day in Crewe on 16 <sup>th</sup> October 2016 and spoke of personal experience of pancreatic cancer – no reimbursement. [20/03/2017]	Personal non-financial, non-specific	Declare and participate
Lesley	Lay member	Attended the PCUK Patient and Carer Board in November 2016	Personal financial,	Declare and participate

Committee membership list – Pancreatic Cancer Guideline Committee

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Goodburn		– reimbursed travel expenses [20/03/2017]	non-specific	(expenses within NICE Travel and Subsistence Policy)
Lesley Goodburn	Lay member	Working with the National Council for Palliative Care to develop a play, film and educational resources based on my husband Seth's and my experience of pancreatic cancer. The film and educational resources have been developed via partnership with the National Council for Palliative Care, Pancreatic Cancer UK, Leeds Teaching Hospital, St Giles Hospice and NHS England. [20/03/2017]	Personal non-financial, non-specific	Declare and participate (end of life care is not covered in this guideline)
Lesley Goodburn	Lay member	Recorded a number of radio and TV pieces about her experience with end of life care with her husband who passed away as a result of pancreatic cancer. [20/03/2017]	Personal non-financial, non-specific	Declare and participate (end of life care is not covered in this guideline)
Anna Jewell	Lay member	The Charity that I work for is Pancreatic Cancer UK and they have received a small amount funding in the last 12 months from several pharmaceutical companies. This funding was used to support holding training events and conferences that we provide for health professionals. The companies did not get input into the content of the training events/conferences. None of the money was used to fund staff salaries. The companies include Celgene, Baxalta, Vitaflo and Mylan. [declared on application 25.2.16]	Non-personal financial specific	Declare and participate as companies only provide financial support for education events – no input into content
Anna Jewell	Lay member	Member of the Public Health England expert advisory group on cancer symptoms [declared on application 25.2.16]	Non-financial personal non-specific	Declare and participate
Anna Jewell	Lay member	Member of the NCIN clinical reference group for	Non-financial	Declare and participate

Committee membership list – Pancreatic Cancer Guideline Committee

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
		hepatobiliary cancers [declared on application 25.2.16]	personal non-specific	
Anna Jewell	Lay member	Has been named on a variety of press releases on behalf of employer – Pancreatic Cancer UK [declared on application 25.2.16]	Non-financial personal specific	Declare and participate
Anna Jewell	Lay member	Named on a press release about NICEs technology appraisal decision on nabpaclitaxel [declared on application 25.2.16]	Non-financial personal specific	Withdraw from discussion of topics which include abraxane as an intervention
Anna Jewell	Lay member	Pancreatic Cancer UK are funding a project being led by Derek Manas to collect data on the use of IRE in pancreatic cancer. As part of this project, has been involved in a couple of meetings and teleconferences with Angiodynamics (manufacturers of equipment used to delivery IRE). Will not participate in any more of these meetings for the duration of the guideline [1.4.16]	Non-financial personal specific	Declare and participate IRE covered by an IP that says use only in research so not being investigated by the guideline
Anna Jewell	Lay member	Presented on the role of information for pancreatic cancer patients at the Central European Cooperative Oncology Group (CECOG), Pancreas Academy in November 2016. Received reimbursement of travel and accommodation and an honorarium payment for speaking which went to Pancreatic Cancer UK	Non-personal financial, non-specific	Declare and participate - expenses within NICE expenses and hospitality policy and CECOG does not manufacture any products (its interests are education and clinical trials and honorarium not personally received)

Committee membership list – Pancreatic Cancer Guideline Committee

<b>Name</b>	<b>Job title, organisation</b>	<b>Declarations of Interest, date declared</b>	<b>Type of interest</b>	<b>Decision taken</b>
Anna Jewell	Lay member	Presented on the role of information for pancreatic cancer patients at the Central European Cooperative Oncology Group (CECOG), Pancreas Academy in November 2016. Received reimbursement of travel and accommodation and an honorarium payment for speaking which went to Pancreatic Cancer UK [DOI 13/12/2016]	Personal financial, non-specific	Declare and participate - expenses within NICE expenses and hospitality policy and CECOG does not manufacture any products (its interests are education and clinical trials and honorarium not personally received)
Anna Jewell	Lay member	AngioDynamics sponsored Pancreatic Cancer UK's Annual Summit and Pancreatic Cancer Study Day [20/03/2017]	Non-personal financial, non-specific	Declare and participate
Anna Jewell	Lay member	Celgene sponsored Pancreatic Cancer UK's Annual Summit and Supporter Event. [20/03/2017]	Non-personal financial, non-specific	Declare and participate
Anna Jewell	Lay member	Immunovia sponsored Pancreatic Cancer UK's Pancreatic Cancer Study Day. [20/03/2017]	Non-personal financial, non-specific	Declare and participate
Anna Jewell	Lay member	Mylan sponsored our Annual Summit £10,000 and Pancreatic Cancer Study Day. [20/03/2017]	Non-personal financial, non-specific	Declare and participate
Anna Jewell	Lay member	NuCana sponsored Pancreatic Cancer UK's Annual Summit. [20/03/2017]	Non-personal financial, non-specific	Declare and participate
Anna Jewell	Lay member	Shire sponsored Pancreatic Cancer UK's Annual Summit and Pancreatic Cancer Study Day. [20/03/2017]	Non-personal financial, non-specific	Declare and participate
Anna Jewell	Lay member	Attending a meeting with Shire	Personal	Declare and



Committee membership list – Pancreatic Cancer Guideline Committee

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
		on 7th March about sponsoring a survey of the information and supportive care needs of pancreatic cancer patients that we have commissioned Oxford Brookes University and The Picker Institute to fund. I am the lead for this survey project. [20/03/2017]	non-financial, specific	participate
Anna Jewell	Lay member	Have become a Patient and public involvement member of the HPB Clinical reference group, NHS England. [20/03/2017]	Personal non-financial, non-specific	Declare and participate
Anna Jewell	Lay member	Provided some information on one of our funded projects to a report being put together by a group of experts called 'Transforming the cancer cycle'. The group was chaired by Katherine Murphy, Chief Executive of the Patients association and the report is available to download from their website. As a result of this I was quoted in a sponsored article in the HSJ. This work was funded by Bristol Myers Squibb. However neither I nor Pancreatic Cancer UK received any funds for our contribution to this report. [11/05/2017]	Personal non-financial, non-specific	Declare and participate
Anna Jewell	Lay member	Bristol Myers Squibb and Celgene have each given £5000 to support the launch event of the Less Survivable Cancers Taskforce in Westminster being held on 19th July 2017.  The Taskforce is a partnership of Pancreatic Cancer UK, The British Liver Trust, Action Against Heartburn, Core and The Brain Tumour Charity. I am Chair of the steering group for the Taskforce. The funding was secured by the fundraising team at Pancreatic Cancer UK.	Non-personal financial, non-specific	Declare and participate

Committee membership list – Pancreatic Cancer Guideline Committee

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
		[19/07/2017]		
Anna Jewell	Lay member	Pancreatic Cancer UK funds a project being run by a team at the Freeman Hospital in Newcastle to collect a registry of data on the use of irreversible electroporation in pancreatic cancer (IRE). There is a user group of clinicians that use this procedure and they held a meeting at our offices in May 2017 which I attended. Angiodynamics the manufacturer of IRE attended this meeting and provided the catering (sandwiches). [19/07/2017]	Non-personal financial, non-specific	Declare and participate
Suzanne Joharchi	Lay member	None		
Laura McGeeney	Specialist Pancreatic Dietician	Conference registration fees, hotel and travel expenses for the Pancreatic Society of Great Britain and Ireland in November 2015 were paid by the Nutrition Interest Group of the Pancreatic Society of Great Britain and Ireland (NIGPS) with money from a grant they received from Mylan. [declared on application 8.2.16]	Non-personal financial specific	Declare and participate
Laura McGeeney	Specialist Pancreatic Dietician	We have reps from companies that make nutritional supplements and enteral feeds come to our monthly departmental meetings, they sometimes bring lunch (sandwiches etc), I attend these meetings and eat the lunch they bring. [declared on application 8.2.16]	Non-financial personal non-specific	Declare and participate
Laura McGeeney	Specialist Pancreatic Dietician	Via an educational grant to NIGPS Mylan have funded food and delegate packs for education sessions I have taught on. [declared on application 8.2.16]	Non-financial personal non-specific	Declare and participate
Laura McGeeney	Specialist Pancreatic Dietician	Recently joined the Medical Advisory Board of Pancreatic Cancer UK but have not yet undertaken any activity as part	Non-financial personal specific	Declare and participate

Committee membership list – Pancreatic Cancer Guideline Committee

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
		of this. [declared on application 8.2.16]		
Laura McGeeney	Specialist Pancreatic Dietician	Secretary of the Nutrition Interest Group of the Pancreatic Society of Great Britain and Ireland (NIGPS) [declared on application 8.2.16]	Non-financial personal specific	Declare and participate
Laura McGeeney	Specialist Pancreatic Dietician	With two other dieticians, wrote a patient information sheet on PERT (approx. 5 years ago) which was formatted, printed and distributed by Abbot and Mylan Pharmaceuticals. Companies has no input into the content of the information sheet	Non-financial personal specific	Declare and participate
Laura McGeeney	Specialist Pancreatic Dietician	Conference fees and accommodation were paid by the Nutrition Interest Group of the Pancreatic Society (NIGPS) for me to attend the annual meeting. I am secretary of NIGPS and we had a committee meeting the day before so my travel was also paid for me to be able to attend this.  The agenda can be found here - <a href="http://www.psqbi2017.com/2207">http://www.psqbi2017.com/2207</a>  This payment came from membership fees to NIGPS.  [25.01.2018]	Personal, financial, specific	Declare and participate  Expenses within the NICE non-staff travel, subsistence and general expenses policy.
Dr Somnath Mukherjee	Senior Clinical Researcher & Consultant Clinical Oncologist, CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford & Churchill Hospital	Chief Investigator of the SCALOP-2 trial (A multi-centre randomised study of induction chemotherapy followed by capecitabine (+/-nelfinavir) with high or standard dose radiotherapy for locally advanced non-metastatic pancreatic cancer). Funded by Celgene and CRUK. Involved in designing the trial protocol. [declared on application 4.2.16]	Non-personal financial specific	Withdraw from discussion of topics that include nelfinavir as an intervention
Dr Somnath	Senior Clinical	Co-applicant on the NEO-	Non-	Declare and

Committee membership list – Pancreatic Cancer Guideline Committee

<b>Name</b>	<b>Job title, organisation</b>	<b>Declarations of Interest, date declared</b>	<b>Type of interest</b>	<b>Decision taken</b>
Mukherjee	Researcher & Consultant Clinical Oncologist, CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford & Churchill Hospital	Scope trial (A randomised Phase II study of two preoperative chemoradiotherapy regimes (oxaliplatin and capecitabine followed by radiotherapy with either oxaliplatin and capecitabine or paclitaxel and carboplatin) for resectable oesophageal cancer.). Funded by CRUK. Involved in designing the trial protocol. [declared on application 4.2.16]	personal financial non-specific	participate
Dr Somnath Mukherjee	Senior Clinical Researcher & Consultant Clinical Oncologist, CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford & Churchill Hospital	Co-applicant on the CHARIOT trial (A Phase I trial of ATR inhibitor VX970 and radiotherapy in oesophageal cancer). Trial currently in set-up. [declared on application 4.2.16]	Non-personal financial non-specific	Declare and participate
Dr Somnath Mukherjee	Senior Clinical Researcher & Consultant Clinical Oncologist, CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford & Churchill Hospital	Member of the ASCO writing committee for their guideline on advanced pancreatic cancer. [declared on application 4.2.16]	Non-financial personal specific	Declare and participate
Dr Somnath Mukherjee	Senior Clinical Researcher & Consultant Clinical Oncologist, CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford & Churchill Hospital	Invited speaker at various events in 2015, on behalf of Celgene, to report on the SCALOP-2 trial. Fee received for one meeting – and reimbursement of travel expenses. No promotion of any particular intervention. [declared on application 4.2.16]	Non-personal financial specific	Withdraw from discussion of topics that include nelfinavir as an intervention
Dr Somnath Mukherjee	Senior Clinical Researcher & Consultant Clinical Oncologist, CRUK/MRC	Member of the NCRI upper GI clinical studies group and the pancreatic subgroup. [declared on application 4.2.16]	Non-financial personal specific	Declare and participate

Committee membership list – Pancreatic Cancer Guideline Committee

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
	Oxford Institute for Radiation Oncology, University of Oxford & Churchill Hospital			
Dr Somnath Mukherjee	Senior Clinical Researcher & Consultant Clinical Oncologist, CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford & Churchill Hospital	On the panel for the ESTRO European Radiotherapy guidelines for pancreatic cancer. [declared on application 4.2.16]	Non-financial personal specific	Declare and participate
Dr Somnath Mukherjee	Senior Clinical Researcher & Consultant Clinical Oncologist, CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford & Churchill Hospital	Chief investigator for the ARC II trial (A Phase II study in patients with locally advanced pancreatic carcinoma: Akt-inhibition by Nelfinavir plus chemoradiation with gemcitabine and cisplatin). Not involved in designing the trial protocol as took over as CI towards the end. Funded by University of Oxford. This study is just about to be published. [1.4.16]	Non-personal financial specific	Declare and participate as not involved in designing trial protocol and trial not funded by industry
Dr Somnath Mukherjee	Senior Clinical Researcher & Consultant Clinical Oncologist, CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford & Churchill Hospital	Co-investigator for ESPAC-5F Four arm, prospective, multicentre, randomised Phase II trial of immediate surgery compared with neoadjuvant chemotherapies and neoadjuvant chemoradiotherapy. Funded by Cancer Research UK [1.4.16]	Non-personal financial specific	Declare and participate as not involved in designing trial protocol and trial not funded by industry
Dr Somnath Mukherjee	Senior Clinical Researcher & Consultant Clinical Oncologist, CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford & Churchill	Co-applicant (wrote the clinical context information) on successful pre-clinical grants from Pancreatic Cancer UK to look at novel imaging in mice [1.4.16]	Non-personal financial non-specific	Declare and participate

Committee membership list – Pancreatic Cancer Guideline Committee

<b>Name</b>	<b>Job title, organisation</b>	<b>Declarations of Interest, date declared</b>	<b>Type of interest</b>	<b>Decision taken</b>
	Hospital			
Dr Somnath Mukherjee	Senior Clinical Researcher & Consultant Clinical Oncologist, CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford & Churchill Hospital	Assisted Pancreatic Cancer UK with development of patient information resources and their patient charter [1.4.16]	Non-financial specific	Declare and participate
Dr Somnath Mukherjee	Senior Clinical Researcher & Consultant Clinical Oncologist, CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford & Churchill Hospital	Joint chief applicant on request for funding from CRUK for the SCOPE2 trial (oesophageal cancer) [1.4.16]	Non-personal financial non-specific	Declare and participate
Dr Somnath Mukherjee	Senior Clinical Researcher & Consultant Clinical Oncologist, CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford & Churchill Hospital	Received an honorarium from the UK Oncology Forum for presenting an update on clinical trials in oesophago-gastric chemoradiotherapy and the results of the neoscope trial at the 2016 UK Oncology Forum meeting in June 2016 [declared on 12.5.16]	Personal financial non-specific	Declare and participate
Somnath Mukherjee	Senior Clinical Researcher & Consultant Clinical Oncologist, CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford & Churchill Hospital	Principal Investigator: PRECISION Panc network of clinical trials. £10 million investment from Cancer Research UK. Funding from Celgene and Astra Zeneca [11/05/2017]	Non-personal financial, specific	Declare and participate
Dr Kofi Oppong	Consultant Gastroenterologist, Newcastle upon Tyne University Hospitals NHS Trust	Flight and hotel 2 nights (approx. £600 total value) paid for by Medtronic/Covidien to present my experience of using their new EUS biopsy needle at their internal meeting and to enable me to attend part of the	Non-personal financial specific	Declare and participate

Committee membership list – Pancreatic Cancer Guideline Committee

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
		concurrent European gastroenterology meeting in Barcelona October 2015. Honorarium to be paid to research fund (no personal payment received). [declared on application 6.1.16]		
Dr Kofi Oppong	Consultant Gastroenterologist, Newcastle upon Tyne University Hospitals NHS Trust	£250 honorarium (to be paid to research fund) from Medtronic/Covidien for presenting a talk on EUS guided pancreatic biopsy at a session sponsored by the company at the European EUS meeting Glasgow November 2015. [declared on application 6.1.16]	Non-personal financial specific	Declare and participate
Dr Kofi Oppong	Consultant Gastroenterologist, Newcastle upon Tyne University Hospitals NHS Trust	Submitted an application to Covidien for an investigator led study comparing biopsy yield in pancreatic masses with standard FNA needles compared with new core biopsy needles (both manufactured by Covidien). If application is granted, will be chief investigator and responsible for designing trial protocol. [declared on application 6.1.16]	Non-personal financial specific	If application is successful will need to leave the room for any topics which are comparing FNA needles with core biopsy needles.
Dr Kofi Oppong	Consultant Gastroenterologist, Newcastle upon Tyne University Hospitals NHS Trust	Local PI for the CONCYST trial looking at needle confocal laser endomicroscopy in people with indeterminate pancreatic cysts [declared on application 6.1.16]	Non-personal financial non-specific	Declare and participate
Dr Kofi Oppong	Consultant Gastroenterologist, Newcastle upon Tyne University Hospitals NHS Trust	Chief investigator of study measuring pressure in the portal vein in patients with liver disease. Funded by University of Newcastle Biomedical Research Centre. [declared on application 6.1.16]	Non-personal financial non-specific	Declare and participate
Dr Kofi Oppong	Consultant Gastroenterologist, Newcastle upon Tyne University Hospitals NHS Trust	Is a co-signatory on a research fund held by the hospital Trust. Fund is used to cover expenses for CPD of department members and could be used in future to assist with research into hepatobiliary disease. No direct contributions to fund from industry – only indirect (i.e. any	Non-personal financial non-specific	Declare and participate

Committee membership list – Pancreatic Cancer Guideline Committee

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
		honorariums are paid to research fund rather than received personally). [declared on application 6.1.16]		
Dr Kofi Oppong	Consultant Gastroenterologist, Newcastle upon Tyne University Hospitals NHS Trust	On the British Society of Gastroenterology endoscopy committee, with a special responsibility for ERCP and EUS. No fees received. [declared on application 6.1.16]	Non-financial non-specific	Declare and participate
Dr Kofi Oppong	Consultant Gastroenterologist, Newcastle upon Tyne University Hospitals NHS Trust	Next year will be president of the Pancreatic Society of GB and Ireland. Main responsibility will be to organise their annual meeting. [declared on application 6.1.16]	Non-financial non-specific	Declare and participate
Dr Kofi Oppong	Consultant Gastroenterologist, Newcastle upon Tyne University Hospitals NHS Trust	Attended a meeting on digital cholangioscopy (a technique to enable imaging within the bile duct during ERPC) in April 2016. Travel reimbursed by Boston Scientific (no honorarium received). [declared on 3.5.16]	Personal financial specific	Declare and participate as expenses within reasonable amounts
Dr Kofi Oppong	Consultant Gastroenterologist, Newcastle upon Tyne University Hospitals NHS Trust	Payment of £800 each by Olympus Medical, Boston Scientific and Cook to the Hospital Endoscopy training fund I am a co-signature to. This money was to cover the cost of a North east ERCP network quality improvement meeting that I organised in October 2016. [declared on 24.10.16]	Non-personal financial, non-specific	Declare and participate
Dr Kofi Oppong	Consultant Gastroenterologist, Newcastle upon Tyne University Hospitals NHS Trust	Attended a BSG ERCP quality improvement programme meeting in Belfast in June 2017 as the guest speaker. The meeting was sponsored by Boston Scientific who paid for my flight (£100) and hotel (£100).	Personal financial, non-specific	Declare and participate (expenses within NICE policy)
Dr Kofi Oppong	Consultant Gastroenterologist, Newcastle upon Tyne University Hospitals NHS Trust	Organised a North east regional ERCP quality improvement meeting in July 2017. This meeting was held in a local hotel. Room rental and buffet meal was sponsored by Cook.	Non-personal financial, non-specific	Declare and participate
Dr Kofi	Consultant Gastroenterologist,	As President of the Pancreatic society of Great Britain and	Non-personal	Declare and participate



Committee membership list – Pancreatic Cancer Guideline Committee

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Oppong	Newcastle upon Tyne University Hospitals NHS Trust	Ireland this year I am organising the annual meeting in Newcastle in November 2017. This meeting (as always) is sponsored by a number of pharmaceutical and Device companies. Sponsorship has been sought by the society and obtained from Mylan (£10,000) Boston Scientific (£3000), SheBO (£2000) Medtronic (£2000) Hitachi (£3000) Cook (£3000) Akcea (£3000) , Shire (£3000). Olympus (£3000). These monies are paid directly to the society.	financial, non-specific	
Mr Derek O'Reilly	Consultant Hepatobiliary and Pancreatic Surgeon, Manchester Royal Infirmary, Central Manchester NHS Foundation Trust	Celgene: Attendance at Platform for Exchange of Expertise and Research (PEER) in oncology meeting, London, 16-17 October 2015. Payment of: travel, accommodation, dinner and congress fee. [declared on application 5.1.16]	Personal financial non-specific	Declare and participate
Mr Derek O'Reilly	Consultant Hepatobiliary and Pancreatic Surgeon, Manchester Royal Infirmary, Central Manchester NHS Foundation Trust	Angiodynamics: Attendance at "The NanoKnife Training Lab" at Academic Medical Center (Irreversible Electroporation Training Course). Payment of: travel, accommodation, dinner and congress fee. [declared on application 5.1.16]	Personal financial non-specific	Declare and participate
Mr Derek O'Reilly	Consultant Hepatobiliary and Pancreatic Surgeon, Manchester Royal Infirmary, Central Manchester NHS Foundation Trust	Organiser of the Manchester Pancreatic Cancer Symposium, due April 14th 2016. Commercial sponsors: Mylan, Angiodynamics, Pancreatic Cancer UK, Medtronic, Pharmacyclics, OncoDNA. [8.4.16]	Non-personal financial specific	Declare and participate as companies only provide financial support for events – no input into content
Mr Derek O'Reilly	Consultant Hepatobiliary and Pancreatic Surgeon, Manchester Royal Infirmary, Central Manchester NHS Foundation Trust	Member of Medical Advisory board for the charity, Pancreatic Cancer UK (no payment) [8.4.16]	Non-financial personal specific	Declare and participate

Committee membership list – Pancreatic Cancer Guideline Committee

<b>Name</b>	<b>Job title, organisation</b>	<b>Declarations of Interest, date declared</b>	<b>Type of interest</b>	<b>Decision taken</b>
Mr Derek O'Reilly	Consultant Hepatobiliary and Pancreatic Surgeon, Manchester Royal Infirmary, Central Manchester NHS Foundation Trust	Chief investigator: Prehabilitation in HPB Surgery: An Integrated program of Nutritional support; Exercise and improved general well-being; and Screening for anxiety and depression, right across the four phases of: Prehabilitation, Enhanced recovery, Recovery/reablement and Living with and beyond cancer. Funded by Macmillan [8.4.16]	Non-personal financial non-specific	Declare and participate
Mr Derek O'Reilly	Consultant Hepatobiliary and Pancreatic Surgeon, Manchester Royal Infirmary, Central Manchester NHS Foundation Trust	Chief investigator: ACE Manchester Cancer Jaundice Pathway. Funded by NHS England/CRUK [8.4.16]	Non-personal financial non-specific	Declare and participate
Mr Derek O'Reilly	Consultant Hepatobiliary and Pancreatic Surgeon, Manchester Royal Infirmary, Central Manchester NHS Foundation Trust	Principal investigator and Trial Steering Committee member: PANasta trial: Cattall Warren versus Blumgart techniques of pancreatico-jejunostomy following pancreato-duodenectomy – a double blinded multi centred trial. Funded by National Cancer Research Institute [8.4.16]	Non-personal financial specific	Declare and participate as no supervisory responsibility in the trial
Mr Derek O'Reilly	Consultant Hepatobiliary and Pancreatic Surgeon, Manchester Royal Infirmary, Central Manchester NHS Foundation Trust	Principal investigator ESPAC-5: Four arm, prospective, multicentre, randomised, feasibility trial of immediate surgery compared with neoadjuvant chemotherapies and neoadjuvant chemoradiotherapy. NCRI funded. [8.4.16]	Non-personal financial specific	Declare and participate as no supervisory responsibility in the trial
Mr Derek O'Reilly	Consultant Hepatobiliary and Pancreatic Surgeon, Manchester Royal Infirmary, Central Manchester NHS Foundation Trust	National Confidential Enquiry into Patient Outcomes and Death (NCEPOD): Currently, National Clinical Co-ordinator (Surgery), responsible for the Acute Pancreatitis Study, due for launch in July 2016. [8.4.16]	Non-personal financial specific	Declare and participate
Mr Derek O'Reilly	Consultant Hepatobiliary and Pancreatic	Pathway Clinical Director for HPB, Manchester Cancer. Manchester Cancer is an	Non-personal financial	Declare and participate

Committee membership list – Pancreatic Cancer Guideline Committee

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
	Surgeon, Manchester Royal Infirmary, Central Manchester NHS Foundation Trust	integrated Cancer system for the 10 hospital Trusts serving the 3.5 million people in the Greater Manchester & Cheshire region. [8.4.16]	non-specific	
Mr Derek O'Reilly	Consultant Hepatobiliary and Pancreatic Surgeon, Manchester Royal Infirmary, Central Manchester NHS Foundation Trust	Received an honorarium from Mylan for giving a lecture on acute and chronic pancreatitis in August 2016 [21.08.16]	Personal financial non-specific	Declare and participate
Mr Derek O'Reilly	Consultant Hepatobiliary and Pancreatic Surgeon, Manchester Royal Infirmary, Central Manchester NHS Foundation Trust	Received an honorarium from Mylan for speaking at training event on pancreatitis, November Manchester [GCM7 13.12.2016]	Financial personal, non-specific	Declare and participate
Mr Derek O'Reilly	Consultant Hepatobiliary and Pancreatic Surgeon, Manchester Royal Infirmary, Central Manchester NHS Foundation Trust	Received travel, accommodation and honorarium from Mylan for speaking on NCEPOD report on acute pancreatitis, November 2016, Belfast. [GCM7 13.12.2016]	Financial personal, non-specific	Declare and participate
Mr Derek O'Reilly	Consultant Hepatobiliary and Pancreatic Surgeon, Manchester Royal Infirmary, Central Manchester NHS Foundation Trust	Attended a meeting on HPB cancer in November 2016 which was sponsored by Myla and Angiodynamics (no role in agenda). Sponsorship was for the venue for the meeting no money received personally. [GCM7 13.12.2016]	Non-personal financial, specific	Declare and participate (expenses within NICE expenses and hospitality policy)
Mr Derek O'Reilly	Consultant Hepatobiliary and Pancreatic Surgeon, Manchester Royal Infirmary, Central Manchester NHS Foundation Trust	Received travel and accommodation expenses and an honorarium from the Central European Cooperative Oncology Group (CECOG) to attend a conference on pancreatic cancer in November 2016. [GCM7 13.12.2016]	Non-personal financial, non-specific	Declare and participate - expenses within NICE expenses and hospitality policy and CECOG does not manufacture any products (its interests are

Committee membership list – Pancreatic Cancer Guideline Committee

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
				education and clinical trials)
Derek O'Reilly	Consultant Hepatobiliary and Pancreatic Surgeon, Manchester Royal Infirmary, Central Manchester NHS Foundation Trust	Received an honorarium from Mylan for speaking at training event on pancreatitis, November Manchester [DOI 13/12/2016]	Financial personal, non-specific	Declare and participate
Derek O'Reilly	Consultant Hepatobiliary and Pancreatic Surgeon, Manchester Royal Infirmary, Central Manchester NHS Foundation Trust	Received travel, accommodation and honorarium from Mylan for speaking on NCEPOD report on acute pancreatitis, November 2016, Belfast [DOI 13/12/2016]	Financial personal, non-specific	Declare and participate
Derek O'Reilly	Consultant Hepatobiliary and Pancreatic Surgeon, Manchester Royal Infirmary, Central Manchester NHS Foundation Trust	Attended a meeting on HPB cancer in November 2016 which was sponsored by Myla and Angiodynamics (no role in agenda). Sponsorship was for the venue for the meeting no money received personally. [DOI 13/12/2016]	Non-personal financial, specific	Declare and participate (expenses within NICE expenses and hospitality policy)
Derek O'Reilly	Consultant Hepatobiliary and Pancreatic Surgeon, Manchester Royal Infirmary, Central Manchester NHS Foundation Trust	Received travel and accommodation expenses and an honorarium from the Central European Cooperative Oncology Group (CECOG) to attend a conference on pancreatic cancer in November 2016. [DOI 13/12/2016]	Personal financial, non-specific	Declare and participate - expenses within NICE expenses and hospitality policy and CECOG does not manufacture any products (its interests are education and clinical trials)
Derek	Consultant	Angiodynamics: Attendance at	Personal	Declare and

Committee membership list – Pancreatic Cancer Guideline Committee

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
O'Reilly	Hepatobiliary and Pancreatic Surgeon, Manchester Royal Infirmary, Central Manchester NHS Foundation Trust	<p>"The NanoKnife Training Lab" at Louisville, Kentucky, USA. (Irreversible Electroporation Training Course). Payment of: travel, accommodation, dinner and congress fee, 16 December 2016.</p> <p>Note: Irreversible Electroporation is not a topic of the Pancreatic Cancer Guidelines Committee. [20/03/2017]</p>	financial, non-specific	participate. (Expenses and travel within NICE Hospitality Policy and Travel and Subsistence Policy)
Derek O'Reilly	Consultant Hepatobiliary and Pancreatic Surgeon, Manchester Royal Infirmary, Central Manchester NHS Foundation Trust	Principal Investigator: PRECISION Panc network of clinical trials. £10 million investment from Cancer Research UK. Funding from Celgene and Astra Zeneca. [11/05/2017]	Non-personal financial, specific	Declare and participate
Derek O'Reilly	Consultant Hepatobiliary and Pancreatic Surgeon, Manchester Royal Infirmary, Central Manchester NHS Foundation Trust	Honorarium for speaking at Pancreatic Cancer Update, Preston 04/10/2017 from Mylan [DOI 11/10/2017]	Personal financial, non-specific	Declare and participate
Derek O'Reilly	Consultant Hepatobiliary and Pancreatic Surgeon, Manchester Royal Infirmary, Central Manchester NHS Foundation Trust	Travel, accommodation to speak at BSG Pancreatic Cyst workshop, London 25/9/2017 [DOI 11/10/2017]	Personal financial, non-specific	Declare and participate
Derek O'Reilly	Consultant Hepatobiliary and Pancreatic Surgeon, Manchester Royal Infirmary, Central Manchester NHS Foundation Trust	Travel, accommodation to speak on Acute Pancreatitis at Emergency Surgical Conference, Oxford, 18/09/2017 [DOI 11/10/2017]	Personal financial, non-specific	Declare and participate
Derek O'Reilly	Consultant Hepatobiliary and Pancreatic Surgeon, Manchester Royal Infirmary, Central Manchester NHS	Travel & accommodation to attend Precision–Panc launch meeting, Glasgow, 24/07/2017 [DOI 11/10/2017]	Personal financial, non-specific	Declare and participate

Committee membership list – Pancreatic Cancer Guideline Committee

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
	Foundation Trust			
Derek O'Reilly	Consultant Hepatobiliary and Pancreatic Surgeon, Manchester Royal Infirmary, Central Manchester NHS Foundation Trust	Travel & accommodation to attend Oncology Forum, Birmingham 15-16/06/2017 [DOI 11/10/2017]	Personal financial, non-specific	Declare and participate
Derek O'Reilly	Consultant Hepatobiliary and Pancreatic Surgeon, Manchester Royal Infirmary, Central Manchester NHS Foundation Trust	Travel & accommodation to attend LIMAX (Liver function) workshop, Mainz, Germany, 22/05/2017, from HuMedics. [DOI 11/10/2017]	Personal financial, non-specific	Declare and participate
Philip Whelan	Macmillan Clinical Nurse Specialist, Royal Liverpool University Hospital	Attended an advisory board for Abbott in March 2015 about the use of Creon. Fee was donated to a support group for pancreatic cancer patients in Liverpool [declared on application 22.2.16]	Non-personal financial specific	Declare and participate
Philip Whelan	Macmillan Clinical Nurse Specialist, Royal Liverpool University Hospital	Reviews content of patient information resources for Pancreatic Cancer UK and Macmillan [declared on application 22.2.16]	Non-financial personal specific	Declare and participate
Philip Whelan	Macmillan Clinical Nurse Specialist, Royal Liverpool University Hospital	Has spoken, on behalf of Macmillan, at a variety of charity events to raise awareness of cancer in general. No fees received [declared on application 22.2.16]	Non-financial personal specific	Declare and participate
Philip Whelan	Macmillan Clinical Nurse Specialist, Royal Liverpool University Hospital	Presented on the role of Cancer Nurse Specialists in pancreatic cancer and UK services at the Central European Cooperative Oncology Group (CECOG), Pancreas Academy in November 2016. Received reimbursement of travel and accommodation (no fee received) [GCM7 13.12.2016]	Personal financial, non-specific	Declare and participate (expenses within NICE expenses and hospitality policy)
Philip Whelan	Macmillan Clinical Nurse Specialist, Royal Liverpool University Hospital	Presented on the role of Cancer Nurse Specialists in pancreatic cancer and UK services at the Central European Cooperative Oncology Group (CECOG), Pancreas Academy in	Personal financial, non-specific	Declare and participate (expenses within NICE expenses and

Committee membership list – Pancreatic Cancer Guideline Committee

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
		November 2016. Received reimbursement of travel and accommodation (no fee received) [DOI 13/12/2016]		hospitality policy)

**Date last reviewed:** 25/01/2018